RecruitingPhase 4NCT06431477

Efficacy and Safety of Telmisartan Compared With Losartan

A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared With Losartan in Patients With Diabetic Nephropathy and Hypertension

Sponsor

Chong Kun Dang Pharmaceutical

Enrollment

98 participants

Start Date

Apr 19, 2023

Study Type

INTERVENTIONAL

Conditions

Hypertension Diabetic Nephropathies

Summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Eligibility

Min Age: 19 YearsMax Age: 75 Years

Inclusion Criteria3

Male of Female subjects aged ≥19 or \<75
Type II Diabetes Mellitus subjects who have been taken medicine
Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF

Exclusion Criteria6

Subjects with Type I Diabetes Mellitus
Subjects with Primary hyper-aldosteronism
Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening
Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period
Subjects who received other clinical trial drugs within 28 days of screening visit
Subjects who are unable to participate in this clinical trial at the discretion of the investigator.